Chronic intraperitoneal administration of imatinib in the AD mouse model APPSwe/PSEN1ΔE9 (APP/PS1) reduced behavioral deficits and decreased AβOs accumulation in the APP/PS1 mice brain and blood (Cancino et al., 2008; Estrada et al., 2016). This evidence concerns the gene APP and Alzheimer disease.